Back to search

Aristotle University Of Thessaloniki (AUTH)

Δραστηριότητα συστηματικού ερυθηματώδους λύκου: στάθμιση νεότερων ανοσολογικών παραμέτρων

Abstract

dc:description

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease,primarily affecting women of reproductive age. Disease incidence ranges from 1 to10/100000 persons/year, while prevalence is estimated to be 20 to 70 patients/100000population. The exact etiopathogenesis remains unknown; however it is consideredthat the effect of an exogenous factor in genetically predisposed individuals may leadto the breakdown of immunological tolerance, resulting to the activation of theimmune system against self-antigens and the generation of autoreactive lymphocytes.Immune system abnormalities refer to practically all immune cells of the innate andadaptive immunity, consequently leading to polyclonal activation of B cells,autoantibody production, immune complexes formation and tissue damage.Immune tolerance impairment is the basic prerequisite for the disease-relatedautoreactivity and is mainly mediated by T regulatory cells (Tregs), for which moststudies demonstrated quantitive and/or qualitive defects in SLE. The correlation ofTregs with disease activity was the focus of several studies with controversial results.However, existing studies were not designed to assess Tregs as immunological toolsfor evaluating disease activity or to address their value in certain disease phenotypes.This lack of relevant data comprised the basis for the design of the experimentalprotocol of this Thesis.Aim of this study was the prospective evaluation of novel immunologicalparameters, such as Tregs and their signature cytokines IL-6, IL-10 and TGF-β, in theassessment of disease activity in SLE. Secondary purpose was to address the role ofantibodies against phosphatidylserine/prothrombin complex in the thromboticmanifestations of these patients.Analysis showed that Tregs were significantly lower in patients with activedisease (SLEDAI>5), in comparison to patients with mild or no disease activity andhealthy controls (0.66±0.23% vs. 1.12±0.33% vs. 1.49±0.19, p<0.001). Correlationco-efficient r was strongly negative (r=-0.644), underlining the influence of these cellsin disease severity. In regard to other disease parameters, Tregs were weakly and notsignificantly correlated to ESR (r=-0.363), IgG (r=-0.189), C3 (r=0.313) and C4d(r=0.302). Moreover, Tregs were marginally decreased in patients with positive antidsDNAantibodies (p=0.009). Tregs were weakly correlated to patients’ age (r=0.236) and disease duration (r=0.223). Furthermore, a weak negative relation withSLICC/ACR (r=-0.118) was observed.To address their value as potential biomarkers, Tregs alterations were assessedin cases of altered (relapse, remission) and unaltered disease activity. In regard tolupus flares, 37 separate cases of disease relapse in 31 patients were analyzed.SLEDAI was significantly increased, while Tregs were significantly reduced(p<0.001). Data analysis showed that only SLEDAI and Tregs were significantlyaltered during relapse, in comparison to other disease activity parameters. Tregs werereduced relatively to their initial numbers in 36 from 37 relapses (sensitivity 97.3%).Furthermore, Tregs were practically halved during relapse.In regard to disease remission, 44 separate cases in 35 patients were analyzed.SLEDAI was significantly reduced, while Tregs were increased (p<0.001). Furtherdata analysis showed that only SLEDAI, Tregs and ESR were significantly alteredduring remission, in contrast to other disease activity parameters. Tregs wereincreased in all cases of remission (sensitivity 100%). On the contrary, mean changeof ESR was 20.2±25.5mm/h, while its sensitivity was estimated to be 84.1%.In this study, Tregs alterations in patients with unaltered disease activity wereanalyzed for first time in the literature. Patients were subdivided according toSLEDAI (no disease activity n=20 SLEDAI=0, mild disease activity n=15,SLEDAI=1-5 and active disease n=15, SLEDAI>5). Tregs remained unaltered in allcases. Mean percentile change of Tregs in patients with unaltered disease activity was7.3±20.6%. Tregs’ alterations in cases of disease relapse and remission weresignificantly greater than in cases with unaltered disease activity (p<0.001).Data analysis was separately performed in certain SLE phenotypes, such aslupus nephritis (LN) and NPSLE. Tregs were found significantly lower in patientswith active LN (p<0.001). Further analysis in 6 patients with a histological diagnosiswho were administered cyclophosphamide pulse therapy revealed that Tregs weresignificantly increased after the end of therapy, while this change was statisticallysignificant even after the 4th pulse. Moreover, Tregs decrement accompanied clinicalremission with concomitant decrease in SLEDAI and proteinuria.Tregs were significantly lower in patients with active NPSLE (p<0.001).Further analysis of 4 patients with active NPSLE who were administeredcyclophosphamide pulse therapy revealed a significant Tregs increment even from the4th pulse (p<0.001). Tregs increase accompanied clinical remission in all cases. Separate analysis was performed in 9 patients, who were diagnosed after studyinitiation, thus not under any immunomodulating therapy before Tregs assessment. Inthis case, Tregs were found to be at the levels of patients with active disease andsignificantly lower than inactive patients (p<0.001).In regard to the influence of various therapeutic agents on Tregs population, itshould be mentioned that intravenous regimens with methylprednisolone,cyclophosphamide and immunoglobulins led to a significant Tregs increment(p<0.001), in comparison to oral methylprednisolone or hydroxychloroquine. Coadministrationof azathioprine and methylprednisolone significantly increased Tregs(p<0.01) also.In this study, for the first time in the literature, we addressed the time to Tregsrestoration after intravenous regimens with methylprednisolone, cyclophosphamideand IVIGs. It was observed that Tregs repletion was achieved significantly soonerwith methylprednisolone (p<0.001) and IVIGs (p=0.002) in comparison tocyclophosphamide.To address the predictive ability of Tregs in disease relapse, we analyzedseparately the clinical course of 6 inactive patients, in whom Tregs were unexpectedlyfound in low levels. Thorough follow up of these patients for two years revealed thatTregs remained low, while only one patient relapsed. Therefore, the positivepredictive value of Tregs in disease relapse is low (16.7%).In regard to IL-6, correlation co-efficient r with SLEDAI was strongly positiver=0.617. Additionally, IL-6 levels were significantly higher in patients with activedisease (p<0.001). Correlation analysis with other disease parameters revealed apositive relationship with ESR (r=0.466) and a negative relationship with C3 (r=-0.432). IL-6 was significantly higher in patients with positive anti-dsDNA antibodies(p<0.001). Serial measurements of IL-6 in patients with altered disease activityshowed that SLEDAI alterations were followed by parallel alterations of thiscytokine. SLEDAI increment was accompanied by IL-6 increase (p=0.010), whileSLEDAI reduction was followed by IL-6 reduction (p=0.001). In unaltered diseaseactivity, IL-6 was not changed significantly. In LN patients, IL-6 was significantlyincreased in active disease (p<0.001), as was in active NPSLE (p=0.005).In regard to IL-10, significantly higher levels were demonstrated in activepatients (p<0.001). Correlation co-efficient r with SLEDAI was strongly positiver=0.519. Furthermore, IL-10 was strongly related to ESR (r=0.419). Serial measurements of IL-10 in cases of altered disease activity revealed that SLEDAIalterations were followed by analogous alterations of IL-10. In this context, IL-10 wassignificantly increased in disease relapse (p=0.002) and decreased in remission(p=0.007). On the contrary, in cases of unaltered disease activity, IL-10 levels werepractically unchanged (p=0.180). IL-10 levels were found significantly higher inpatients with active LN (p=0.025), while they were positively correlated to the levelof proteinuria (r=0.425). Furthermore, IL-10 was significantly higher in patients withpositive anti-dsDNA antibodies (p<0.001). In regard to NPSLE, IL-10 was higher inpatients with active disease (p=0.224), without reaching statistical significance.Data analysis of TGF-β revealed that it was inversely correlated to SLEDAI(r=-0.404). In this regard, lower levels of TGF-β were detected in active patients(p<0.001). TGF-β was not significantly correlated with other disease activityparameters. Regarding LN, TGF-β was marginally lower in patients with active LN(p=0.034) and, also, in patients with positive anti-dsDNA antibodies (p=0.029). In thecase of NPSLE, levels of TGF-β were not differentiated between active and inactivepatients (p=0.103).Further data analysis was performed in regard to the correlation of thesesignature cytokines (IL-6, IL-10 and TGF-β) with Tregs. IL-6 was inverselycorrelated to Tregs (r=-0.443), underlining its important negative regulation of Tregs’differentiation. IL-10 was also inversely correlated to Tregs (r=-0.328), while TGF-βwas weakly positively correlated to these cells (r=0.336), revealing a more potentregulatory activity in comparison to IL-10.In regard to anti-PS/PT antibodies, it was observed that these are stronglycorrelated with CNS involvement and multiple ischemic infarcts in particular. Inaddition, 54.5% of anti-PS/PT positive patients developed livedo reticularis. On thecontrary, these antibodies did not correlate with spontaneous abortions; only onepatient in our cohort had a history of obstetric complications, while she was alsopositive for other antiphospholipid specificities.In conclusion, CD4+CD25highFOXP3+ Tregs are a reliable immunological toolfor the assessment of disease activity in SLE and may confirm disease relapse and/orremission with high sensitivity. On the opposite, their predictive value in diseaseflares seems quite limited. In addition, Tregs may exert a significant role in thedevelopment and evolution of certain disease phenotypes, such as LN and NPSLE.Tregs restoration after remission induction is independent of the therapeutic regimen used. However, intravenous regimens with methylprednisolone, cyclophosphamideand IVIGs are related to prompt and complete Tregs repletion.In regard to cytokines, IL-6 and IL-10 seem to be less reliable biomarkers ofSLE activity than Tregs. Both cytokines were proved to follow SLEDAI alterations,while IL-6 was strongly related to the presence of anti-dsDNA antibodies and activeLN, and, less convincingly to the activity of NPSLE. On the contrary, IL-10 was notrelated to NPSLE, while it seems to have a role in LN activity. TGF-β is a lessreliable biomarker whereas it may has a role in LN.Finally, increased titers of anti-PS/PT antibodies are related to CNSinvolvement and, in particular, multiple ischemic infarcts, along with the developmentof livedo reticularis.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Tselios, Konstantinos
  • Τσέλιος, Κωνσταντίνος

Subjects

dc:subject × 22

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/38087

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Tselios, Konstantinos; Τσέλιος, Κωνσταντίνος. Δραστηριότητα συστηματικού ερυθηματώδους λύκου: στάθμιση νεότερων ανοσολογικών παραμέτρων. Aristotle University Of Thessaloniki (AUTH), 2013. http://hdl.handle.net/10442/hedi/38087